Cerus Corporation (CERS) Financial Analysis & Valuation | Quarter Chart
Cerus Corporation (CERS)
CERSPrice: $2.07
Fair Value: 🔒
🔒score
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pa... more
Cerus Corporation operates as a biomedical products company. The company focuses on developing and c... more
Description
Shares
| Market Cap | $397.36M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | William Greenman |
| IPO Date | 1997-01-31 | CAGR | 0.13% |
| Employees | 614 | Website | www.cerus.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CERS chart loading...
Fundamentals
Technicals
| Enterprise Value | $422.20M | P/E Ratio | -25.87 |
| Forward P/E | -384 | PEG Ratio | — |
| P/S Ratio | 92.11 | P/B Ratio | 331.71 |
| P/CF Ratio | 3200.6 | P/FCF Ratio | 5351.59 |
| EPS | $-0.08 | EPS Growth 1Y | -22.33% |
| EPS Growth 3Y | -61.8% | EPS Growth 5Y | -78.88% |
| Revenue Growth 1Y | 13.03% | Gross Margin | 0.56% |
| Operating Margin | -0.06% | Profit Margin | -0.1% |
| ROE | -0.34% | ROA | -0.09% |
| ROCE | -0.09% | Current Ratio | 2 |
| Quick Ratio | 1.35 | Cash Ratio | 0.19 |
| Debt/Equity | 1.78 | Interest Coverage | -1.36 |
| Altman Z Score | -4.52 | Piotroski Score | 5 |